Panobinostat clinical trial highlights the challenges towards an HIV cure

The Lancet HIV

Volumn 1, Issue 3, 2014, Pages e103-

  Palmer, Clovis S ^a   Crowe, Suzanne M ^b,c  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; PANOBINOSTAT;

CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CELL PROLIFERATION; CELL STIMULATION; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIREMIA; VIRUS LATENCY;

EID: 84921953628     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(14)00009-5     Document Type: Letter

References (5)

1. Rasmussen TA, Tolstrup M, Brinkmann CR, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 2014; 1: e13-21.
2. Lucera MB, Tilton CA, Mao H, et al. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and effi ciency of postentry viral events. J Virol 2014; 88: 10803-12.
3. Macintyre AN, Gerriets VA, Nichols AG, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and eff ector function. Cell Metab 2014; 20: 61-72.
4. Palmer CS, Ostrowski M, Gouillou M, et al. Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection. AIDS 2014; 28: 297-309.
5. Josefsson L, von Stockenstrom S, Faria NR, et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci USA 2013; 110: E4987-96.